Abstract Number: 1445 • 2019 ACR/ARP Annual Meeting
Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States
Background/Purpose: Tofacitinib was the first Janus kinase (JAK) inhibitor FDA approved for the treatment of RA in November 2012, five- and one-half years later, baricitinib,…Abstract Number: 2400 • 2019 ACR/ARP Annual Meeting
The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results Form a Nationwide Registry
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) should be used for the treatment of rheumatoid arthritis (RA) in combination with conventional synthetic disease modifying anti‑rheumatic drugs…Abstract Number: L05 • 2018 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Reversible Abnormalities of Vascular Function on Cardiac MRI with RA Therapy with Preliminary Suggestion of Greater Improvement with Anti-TNF Compared to MTX/Conventional Therapy – a First, RCT Derived Longitudinal Study
Background/Purpose: We previously reported abnormal cardiac MRI (CMR)-determined aortic stiffness in patients with early, treatment-naive RA1,2. We now report on whether this vascular stiffness is…Abstract Number: 639 • 2018 ACR/ARHP Annual Meeting
Is a Primary Good Response to Nsaids Predictive of the Subsequent Response to the First TNF Inhibitor in Patients with Early Axial Spondyloarthritis ?
Background/Purpose: Good response to NSAIDs is a SpA feature included in classification criteria for axial spondyloarthritis (axSpA). Among patients eligible for a TNF inhibitor (TNFi),…Abstract Number: 2829 • 2018 ACR/ARHP Annual Meeting
The Response to TNF-Blockers Treatment of Spa Patients Is Influenced By the Interplay between HLA-B27 and Gut Microbiota Composition at Baseline
Background/Purpose: The response to TNF-blockers in axial spondyloarthritis (AxSpA) is at least partially influenced by HLA-B27 through a still poorly understood mechanism. Given that HLA-B27…Abstract Number: 921 • 2018 ACR/ARHP Annual Meeting
Multi-Omics Analysis Identifies a Gene Signature Associated with the Clinical Response to Anti-TNF Therapy in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is the most common inflammatory arthritis affecting up to 1% of the population. Tumor Necrosis Factor (TNF) inhibitors have significantly improved…Abstract Number: 2831 • 2018 ACR/ARHP Annual Meeting
High Need for Anti-TNF Therapy after Withdrawal Strategy in Early Peripheral Spondyloarthritis
Background/Purpose: Treatment with TNFi in early stages of peripheral Spondyloarthritis (pSpA) results in higher rates of clinical remission, compared to treatment in more longstanding disease.…Abstract Number: 961 • 2018 ACR/ARHP Annual Meeting
The Association of Biologic Drug-Levels with Infection Risk: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Background/Purpose: High dose tumour necrosis factor inhibitor (TNFi) drugs are associated with an increased serious infection (SI) risk[1]. It is feasible that high biologic…Abstract Number: 2862 • 2018 ACR/ARHP Annual Meeting
Magnitude of Response to TNF Inhibitors in Children with Spondyloarthritis and Sacroiliitis
Background/Purpose: We aimed to quantify the magnitude of biologic effect on sacroiliitis in juvenile SpA by comparing the change in the Spondyloarthritis Research Consortium of…Abstract Number: 1234 • 2018 ACR/ARHP Annual Meeting
Incidence of Conversion of Screening Tests for M. Tuberculosis (PPD, GIF-release assay) in a Metropolitan Cohort of Patients Treated with TNF-α Inhibitors
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are used to reduce the inflammatory process in many autoimmune diseases. Due to the risk of reactivation of…Abstract Number: 2877 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Background/Purpose: RA patients who are intolerant or have an inadequate response to conventional synthetic DMARDs (csDMARDs) can be treated with a biologic DMARD (bDMARD). Tumor…Abstract Number: 1450 • 2018 ACR/ARHP Annual Meeting
Clinical Radiology Reports Are Unreliable for Assessment of Radiographic Structural Progression in US Veterans with Rheumatoid Arthritis Initiating Tumor Necrosis Factor Inhibitor Therapy
Background/Purpose: Rheumatologists rely on hand radiograph findings including bone erosions (BE) and joint space narrowing (JSN) to make treatment decisions for patients with rheumatoid arthritis…Abstract Number: 2879 • 2018 ACR/ARHP Annual Meeting
Plasma IL-23 and IL-25 Predict Response to Anti-TNF-α Therapy in Rheumatoid Arthritis
Background/Purpose: TNF-α inhibitors are among the most widely used biological-DMARDs in rheumatoid arthritis (RA). Means to predict response would allow for a more effective, targeted…Abstract Number: 1497 • 2018 ACR/ARHP Annual Meeting
PRISM-RA: A Personalized Medicine Test That Accurately Predicts Rheumatoid Arthritis Patients Who Will Not Respond Adequately to Tumor Necrosis Factor Inhibitors
Background/Purpose: Rheumatoid arthritis (RA) is a complex disease affecting about 1.3M adults in the US. The patient population is very heterogeneous; no single drug mechanism…Abstract Number: 2888 • 2018 ACR/ARHP Annual Meeting
Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis
Background/Purpose: In patients with axial spondyloarthritis (axSpA), the use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate (MTX) and sulfasalazine (SSZ), as well…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 29
- Next Page »